These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 16219908)

  • 1. Flavopiridol and histone deacetylase inhibitors promote mitochondrial injury and cell death in human leukemia cells that overexpress Bcl-2.
    Dasmahapatra G; Almenara JA; Grant S
    Mol Pharmacol; 2006 Jan; 69(1):288-98. PubMed ID: 16219908
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potent antileukemic interactions between flavopiridol and TRAIL/Apo2L involve flavopiridol-mediated XIAP downregulation.
    Rosato RR; Dai Y; Almenara JA; Maggio SC; Grant S
    Leukemia; 2004 Nov; 18(11):1780-8. PubMed ID: 15385934
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Contribution of disruption of the nuclear factor-kappaB pathway to induction of apoptosis in human leukemia cells by histone deacetylase inhibitors and flavopiridol.
    Gao N; Dai Y; Rahmani M; Dent P; Grant S
    Mol Pharmacol; 2004 Oct; 66(4):956-63. PubMed ID: 15235103
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Simultaneous activation of the intrinsic and extrinsic pathways by histone deacetylase (HDAC) inhibitors and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) synergistically induces mitochondrial damage and apoptosis in human leukemia cells.
    Rosato RR; Almenara JA; Dai Y; Grant S
    Mol Cancer Ther; 2003 Dec; 2(12):1273-84. PubMed ID: 14707268
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synergistic induction of mitochondrial damage and apoptosis in human leukemia cells by flavopiridol and the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA).
    Almenara J; Rosato R; Grant S
    Leukemia; 2002 Jul; 16(7):1331-43. PubMed ID: 12094258
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Coadministration of histone deacetylase inhibitors and perifosine synergistically induces apoptosis in human leukemia cells through Akt and ERK1/2 inactivation and the generation of ceramide and reactive oxygen species.
    Rahmani M; Reese E; Dai Y; Bauer C; Payne SG; Dent P; Spiegel S; Grant S
    Cancer Res; 2005 Mar; 65(6):2422-32. PubMed ID: 15781658
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Loss of the Bcl-2 phosphorylation loop domain is required to protect human myeloid leukemia cells from flavopiridol-mediated mitochondrial damage and apoptosis.
    Decker RH; Wang S; Dai Y; Dent P; Grant S
    Cancer Biol Ther; 2002; 1(2):136-44. PubMed ID: 12170773
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potentiation of 1-beta-D-arabinofuranosylcytosine-mediated mitochondrial damage and apoptosis in human leukemia cells (U937) overexpressing bcl-2 by the kinase inhibitor 7-hydroxystaurosporine (UCN-01).
    Tang L; Boise LH; Dent P; Grant S
    Biochem Pharmacol; 2000 Nov; 60(10):1445-56. PubMed ID: 11020446
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The histone deacetylase inhibitor MS-275 interacts synergistically with fludarabine to induce apoptosis in human leukemia cells.
    Maggio SC; Rosato RR; Kramer LB; Dai Y; Rahmani M; Paik DS; Czarnik AC; Payne SG; Spiegel S; Grant S
    Cancer Res; 2004 Apr; 64(7):2590-600. PubMed ID: 15059916
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The small-molecule Bcl-2 inhibitor HA14-1 interacts synergistically with flavopiridol to induce mitochondrial injury and apoptosis in human myeloma cells through a free radical-dependent and Jun NH2-terminal kinase-dependent mechanism.
    Pei XY; Dai Y; Grant S
    Mol Cancer Ther; 2004 Dec; 3(12):1513-24. PubMed ID: 15634644
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The cyclin-dependent kinase inhibitor (CDKI) flavopiridol disrupts phorbol 12-myristate 13-acetate-induced differentiation and CDKI expression while enhancing apoptosis in human myeloid leukemia cells.
    Cartee L; Wang Z; Decker RH; Chellappan SP; Fusaro G; Hirsch KG; Sankala HM; Dent P; Grant S
    Cancer Res; 2001 Mar; 61(6):2583-91. PubMed ID: 11289135
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proteasome inhibitors potentiate leukemic cell apoptosis induced by the cyclin-dependent kinase inhibitor flavopiridol through a SAPK/JNK- and NF-kappaB-dependent process.
    Dai Y; Rahmani M; Grant S
    Oncogene; 2003 Oct; 22(46):7108-22. PubMed ID: 14562039
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The cyclin-dependent kinase inhibitor flavopiridol disrupts sodium butyrate-induced p21WAF1/CIP1 expression and maturation while reciprocally potentiating apoptosis in human leukemia cells.
    Rosato RR; Almenara JA; Cartee L; Betts V; Chellappan SP; Grant S
    Mol Cancer Ther; 2002 Feb; 1(4):253-66. PubMed ID: 12467221
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protein kinase C-dependent activation of the tumor necrosis factor receptor-mediated extrinsic cell death pathway underlies enhanced apoptosis in human myeloid leukemia cells exposed to bryostatin 1 and flavopiridol.
    Cartee L; Maggio SC; Smith R; Sankala HM; Dent P; Grant S
    Mol Cancer Ther; 2003 Jan; 2(1):83-93. PubMed ID: 12533676
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The lethal effects of pharmacological cyclin-dependent kinase inhibitors in human leukemia cells proceed through a phosphatidylinositol 3-kinase/Akt-dependent process.
    Yu C; Rahmani M; Dai Y; Conrad D; Krystal G; Dent P; Grant S
    Cancer Res; 2003 Apr; 63(8):1822-33. PubMed ID: 12702569
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanism and functional role of XIAP and Mcl-1 down-regulation in flavopiridol/vorinostat antileukemic interactions.
    Rosato RR; Almenara JA; Kolla SS; Maggio SC; Coe S; Giménez MS; Dent P; Grant S
    Mol Cancer Ther; 2007 Feb; 6(2):692-702. PubMed ID: 17308065
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interactive effects of histone deacetylase inhibitors and TRAIL on apoptosis in human leukemia cells: involvement of both death receptor and mitochondrial pathways.
    Shankar S; Singh TR; Fandy TE; Luetrakul T; Ross DD; Srivastava RK
    Int J Mol Med; 2005 Dec; 16(6):1125-38. PubMed ID: 16273296
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evidence of a functional role for p21WAF1/CIP1 down-regulation in synergistic antileukemic interactions between the histone deacetylase inhibitor sodium butyrate and flavopiridol.
    Rosato RR; Almenara JA; Yu C; Grant S
    Mol Pharmacol; 2004 Mar; 65(3):571-81. PubMed ID: 14978235
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potentiation of the lethality of the histone deacetylase inhibitor LAQ824 by the cyclin-dependent kinase inhibitor roscovitine in human leukemia cells.
    Rosato RR; Almenara JA; Maggio SC; Atadja P; Craig R; Vrana J; Dent P; Grant S
    Mol Cancer Ther; 2005 Nov; 4(11):1772-85. PubMed ID: 16275999
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Extrinsic pathway- and cathepsin-dependent induction of mitochondrial dysfunction are essential for synergistic flavopiridol and vorinostat lethality in breast cancer cells.
    Mitchell C; Park MA; Zhang G; Yacoub A; Curiel DT; Fisher PB; Roberts JD; Grant S; Dent P
    Mol Cancer Ther; 2007 Dec; 6(12 Pt 1):3101-12. PubMed ID: 18065490
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.